24/7 Market News Snapshot 26 June, 2025 – AETHLON MEDICAL INC (NASDAQ:AEMD)

June 26, 2025

DENVER, Colo., 26 June, 2025 (www.247marketnews.com) – (NASDAQ:AEMD) are discussed in this article.
Aethlon Medical Inc. is experiencing a notable surge in its stock performance, achieving an impressive 58.79% increase as it trades at $2.493 following an opening price of $1.58. This rally is characterized by robust trading activity, with approximately 1.37 million shares exchanged, suggesting heightened investor interest and confidence in the company’s growth potential. Analysts are observing strong bullish sentiment, which may indicate sustained upward momentum in the market.

In parallel with its stock market performance, Aethlon Medical has announced significant advancements in its clinical trial endeavors, particularly concerning the Hemopurifier® device used for cancer therapy. The company highlighted the successful treatment of the first three patients in its Hemopurifier® cancer trial, which focuses on individuals with solid tumors that have shown resistance to existing treatments. The trial’s preliminary phase has reached a key milestone, with all participants completing treatment without complications. The Data Safety Monitoring Board is expected to assess the data by mid-2025 to evaluate the feasibility of proceeding to the next patient cohort, demonstrating the trial’s ongoing promise.

Moreover, Aethlon has received regulatory approval from Indian health authorities to initiate a parallel study, further establishing its commitment to pioneering treatments for both cancer and infectious diseases. Aethlon is also exploring the Hemopurifier’s potential in addressing Long COVID through a collaboration with UCSF, indicating a strategic expansion of its applications.

Financially, the company has reported a 26% reduction in operating expenses, reflecting efficient resource management and streamlined operations. As Aethlon continues to improve its financial health and operational efficacy, the prospects for its innovative therapies appear increasingly promising, positioning the company for a transformative year ahead.

Related news for (AEMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.